Matthew Buten serves as the Chief Financial Officer (CFO) at BIOHAVEN LTD, a position he has held since joining the company in 2020. With a robust background in finance and strategic planning, Matthew has been instrumental in steering BIOHAVEN LTD towards sustainable growth and financial stability. Prior to his role at BIOHAVEN LTD, Matthew held several high-profile positions in the finance sector, including a stint as the CFO at a leading pharmaceutical company where he successfully managed the firm's financial operations and led it through a period of significant expansion. At BIOHAVEN LTD, Matthew Buten is responsible for overseeing all aspects of the company's financial strategy, including budgeting, forecasting, and investor relations. His strategic vision has been pivotal in securing funding for critical research and development projects, which have propelled the company to the forefront of the biopharmaceutical industry. Under his leadership, BIOHAVEN LTD has not only improved its financial health but also enhanced its market position, making it a key player in the development of innovative treatments for neurological and neuropsychiatric disorders. Matthew's achievements extend beyond his corporate roles. He is a recognized thought leader in the finance and healthcare sectors, frequently speaking at industry conferences and contributing to leading financial journals. His commitment to excellence and innovation has earned him numerous accolades, including being named one of the top CFOs in the biopharmaceutical industry by a prominent business magazine. Matthew holds an MBA from a top-tier business school and is a certified public accountant, qualifications that have equipped him with the skills necessary to navigate the complex financial landscape of the biopharmaceutical industry.